Nina, Diffuse Large B-Cell Lymphoma Survivor
Nina, Diffuse Large B-Cell Lymphoma Survivor My journey with lymphoma began three days before New York City was on lockdown for the 2020 COVID pandemic –
Related Articles
Transparency and Consolidation Issues Hamper 340B Program in Cancer Care
Since it’s implementation in 1992, the aim of the 340B Drug Pricing Program has been to offer low-income and underserved patient populations with cancer and…
Preparation is Key to Tackle the Transition from Fellow to Attending Physician
A lymphoma hematologist/oncologist who recently transitioned from a fellow to an attending physician shares his experience with the change and tips for fellows.
Shaking Up Gynecologic Cancer Treatment With Mentorship and Patient-Centric Care
Carol Aghajanian, MD, has stayed at the forefront of innovation in gynecologic oncology—and she credits her patients and their conversations in retaining that role.
Abstracts
Learn more about and submit your abstract to the AACR Annual Meeting 2025, held April 25-30, 2025, in Chicago, Illinois.
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.
Key Considerations for the Evolving Treatment Landscape for Relapsed/Refractory Follicular Lymphoma
A panelist discusses how various antibody-drug conjugates, including polatuzumab vedotin, pinatuzumab vedotin, and loncastuximab, have been studied in combination with rituximab for relapsed/refractory follicular lymphoma.…
Community Practice Training During Fellowship Often Falls Short
A hematology fellow discusses findings from 2 surveys he coauthored, which sought to identify gaps in community practice training during hematology/oncology fellowship.
Advancing Cell Therapy Research, Discovery & Innovation : Oncology Times
An abstract is unavailable.
Oncogene Analysis Identifies Clinically Relevant Gene Copy Number Gain Thresholds in NSCLC: With Alec Watson, MD
OncLive serves as the connection to oncology, including groundbreaking cancer news and interviews with top oncologists in multimedia formats.
Inhibiting intracellular CD28 in cancer cells enhances antitumor immunity and overcomes anti-PD-1 resistance via targeting PD-L1
Yang et al. report that the intracellular CD28 in triple negative breast cancer (TNBC) cells promotes PD-L1-mediated immune escape. Inhibition of CD28 in cancer cells decreases…
